Angiogenic and Immunologic Applications of Anti-CD160 Specific Compounds Obtainable From mAb CL1-R2

Abstract

The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.

1 - 53 . (canceled) 
     
     
         54 . A method for inducing or inhibiting, and/or up- or down-regulating the cytokine production of an individual, comprising administering to said individual an anti-CD160 compound selected from the group consisting of anti-CD160 antibody, anti-CD160 antibody fragment, and anti-CD 160 antibody derivative. 
     
     
         55 . The method according to  claim 54 , wherein said cytokine is selected from the group consisting of IFNγ, TNFα, IL-6, and combinations thereof. 
     
     
         56 . The method according to  claim 54 , wherein administering said anti-CD160 compound is for inducing or inhibiting, and/or up- or down-regulating the adaptive immunity potential of said individual. 
     
     
         57 . The method according to  claim 54 , wherein administering said anti-CD160 compound is for the treatment of an infection. 
     
     
         58 . The method according to  claim 54 , wherein said anti-CD160 compound is comprised in a vaccine composition, or intended as a vaccine adjuvant. 
     
     
         59 . The method according to  claim 54 , wherein administering said anti-CD160 compound is for inducing or inhibiting, and/or up- or down-regulating hematopoiesis in said individual. 
     
     
         60 . The method according to  claim 54 , wherein administering said anti-CD160 compound is for the treatment of irradiated individuals and/or for the treatment or prevention of bone marrow aplasia. 
     
     
         61 . The method according to  claim 54 , wherein administering said anti-CD160 compound is for inducing or inhibiting, and/or up- or down-regulating an inflammatory reaction in said individual. 
     
     
         62 . The method according to  claim 54 , wherein administering said anti-CD160 compound is for the treatment of an allergy in said individual. 
     
     
         63 . The method according to  claim 54 , wherein administering said anti-CD160 compound is for inducing a vasodilatation. 
     
     
         64 . The method according to  claim 54 , wherein said anti-CD160 compound is a soluble compound. 
     
     
         65 . The method according to  claim 54 , wherein said anti-CD160 compound is the anti-CD 160 mAb obtainable from hybridoma CNCM I-3204. 
     
     
         66 . The method according to  claim 64 , wherein said anti-CD160 compound is a conservative fragment of mAb CL1-R2 selected from the group consisting of a Fab, a Fab′, a F(ab)2, a F(ab′)2 or a Fv fragment of said mAb CL1-R2. 
     
     
         67 . The method according to  claim 54 , wherein said anti-CD160 compound is a derivative of mAb CL1-R2 comprising all 6 CDRs of CL1-R2. 
     
     
         68 . The method according to  claim 54 , wherein said anti-CD160 compound is an aggregated compound. 
     
     
         69 . A method for activating natural killer cells, comprising contacting a natural killer cell with an anti-CD160 compound selected from the group consisting of anti-CD160 antibody, anti-CD160 antibody fragment, and anti-CD160 antibody derivative.